Patent intelligence · US
US 12311059
Process for the preparation of erythrocytes loaded with one or more substances of pharmaceutical interest and so obtained erythrocytes
Process for the preparation of erythrocytes loaded with one or more substances of pharmaceutical interest and so obtained erythrocytes
Patent details — US 12311059
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 27, 2025
- Expiration
- May 22, 2045
- Applicant
- Quince Therapeutics S.p.A.
- Claims
- 5
- CPC classes
- A61K, A61K31/661, A61K35/18, A61K38/45
Quick answer
US 12311059 (Process for the preparation of erythrocytes loaded with one or more substances of pharmaceutical interest and so obtained erythrocytes) is held by Quince Therapeutics S.p.A.. Status: granted. Granted May 27, 2025. Expires May 22, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Quince Therapeutics S.p.A.
- Grant date
- Expiration
- Claims
- 5
- CPC classes
- A61K, A61K31/661, A61K35/18, A61K38/45, A61K9/5068, A61K9/5089
Frequently asked questions
What is US patent 12311059?
US 12311059 (Process for the preparation of erythrocytes loaded with one or more substances of pharmaceutical interest and so obtained erythrocytes) is held by Quince Therapeutics S.p.A.. Status: granted. Granted May 27, 2025. Expires May 22, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12311059?
Quince Therapeutics S.p.A. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1 pharmaceutical patents for this assignee.
When does US 12311059 expire?
Our index shows an expiration date of May 22, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.